Producing MSC-derived cell therapies: workflows, technologies, and case studies

In this expert roundtable, four highly experienced industry professionals discuss key considerations in mesenchymal stem (or stromal) cell (MSC) manufacturing, including reagent selection, dosing, delivery methods, and final product formulation. The panelists also explore emerging modalities such as induced pluripotent stem cell (iPSC)-derived MSCs, gene-engineered MSCs, and exosome-based therapies, and emphasize the need for cost reduction and scalable manufacturing to improve accessibility and clinical success.

Irana Coletti Malaspina is currently a Field Application Scientist—Latin America for Corning Life Sciences. She has more than 9 years of experience in end-to-end MSC manufacturing for advanced therapy medicinal products.

Shirley Mei has over 20 years of experience in both industry and academia. She is currently a Scientific Investigator in the Regenerative Medicine Program at the Ottawa Hospital Research Institute, where her lab develops and optimizes MSC expansion protocols and investigates how MSCs interact with immune cells.

Tony Ting is the CSO for Kiji Therapeutics, which is developing off-the-shelf engineered cell therapies. He has over 30 years of academic and industry experience in translational science and global regulatory filing including more than 20 years in the cell therapy field, at companies including Takeda, Bone Therapeutics, and Athersys.

Whitney Cary Wilson is a Field Application Scientist at Corning Life Sciences. Previously, Whitney spent 12 years at the UC Davis Institute for Regenerative Cures and was Director of the UC Davis Stem Cell Core. Now, she works with process development groups to optimize production capabilities and cellular scale-up conditions.

Please enter your email to access content Read now